Equillium, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Equillium, Inc. (market cap ~$7.1M) filed its Q2 2026 quarterly report on 2026-08-13 for period ending 2026-06-30. The filing header provides no material financial figures, cash position, revenue, R&D spending, headcount, clinical trial status, or substantive business updates in this excerpt—only SEC administrative metadata and company incorporation details (Delaware, EIN 821554746, SIC 2834 Pharmaceutical Preparations).
Why this rating
No financial data, deal, or operational event disclosed in excerpt. Standard quarterly filing submission is routine administrative disclosure.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.